Australia markets closed

TherapeuticsMD, Inc. (TXMD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.20-0.05 (-0.95%)
At close: 04:00PM EST
5.35 +0.15 (+2.88%)
After hours: 07:32PM EST
Full screen
Trade prices are not sourced from all markets
Previous close5.25
Open5.32
Bid5.15 x 3000
Ask5.40 x 1800
Day's range5.15 - 5.40
52-week range1.99 - 23.00
Volume34,511
Avg. volume141,801
Market cap49.229M
Beta (5Y monthly)1.24
PE ratio (TTM)N/A
EPS (TTM)-21.73
Earnings date08 Mar 2023 - 13 Mar 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.00
  • Business Wire

    TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma

    BOCA RATON, Fla., January 03, 2023--TherapeuticsMD, Inc. (NASDAQ: TXMD) ("TherapeuticsMD," "TXMD" or the "Company"), an innovative, leading women’s healthcare company, today announced that it has completed its previously announced transaction with Mayne Pharma Group Limited ("Mayne Pharma"), an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, pursuant to which TXMD granted Mayne Pharma an exclusive license to commercialize TXMD’s products

  • Business Wire

    TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma

    BOCA RATON, Fla., December 04, 2022--TherapeuticsMD, Inc. (NASDAQ: TXMD) ("TherapeuticsMD," "TXMD" or the "Company"), an innovative, leading women’s healthcare company, today announced that it has entered into definitive agreements to license its products to an affiliate of Mayne Pharma Group Limited ("Mayne Pharma"), an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, for commercialization in the United States. In addition, TXMD has agree

  • Zacks

    TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimates

    TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -53.43% and 30.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?